Introduction
Brucella spp. are aetiological agents of brucellosis, a worldwide zoonosis [1] .
Terrestrial and marine mammals are natural reservoirs for these bacteria. Human contamination usually occurs via direct contact with infected domestic animals or via the digestive route after consumption of contaminated raw milk or milk products.
Pasteurisation of milk and eradication of brucellosis in cattle has dramatically reduced the incidence of human brucellosis in developed countries. However, brucellosis remains endemic and a public health problem in many countries where these prophylactic measures have not been implemented, especially around the Mediterranean Sea, in the Middle East, in central Asia and in some parts of Africa and South America [2] .
Two antibiotic combinations, i.e. doxycycline + rifampicin or doxycycline plus an aminoglycoside (e.g. streptomycin or gentamicin), remain the mainstay in brucellosis therapy [1] . Therapy alternatives may be needed in patients with severe adverse effects as well as in children <8 years old and in pregnant women in whom tetracyclines are contraindicated [1] . On the other hand, relapse rates of 10-15% are still observed with these antibiotic combinations despite prolonged therapy.
Combinations of trimethoprim/sulphamethoxazole (co-trimoxazole) or a macrolide with either rifampicin or an aminoglycoside have been used for decades, but with higher relapse rates [1] . The fluoroquinolones have recently been considered as a promising alternative in the treatment of human brucellosis [3, 4] . These antibiotics display low minimum inhibitory concentrations (MICs) against Brucella spp. in vitro [5] [6] [7] [8] [9] [10] and have good oral bioavailability and a large volume of distribution including in eukaryotic cells where Brucella sp. multiply [11, 12] . They are usually well tolerated
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A c c e p t e d M a n u s c r i p t although, as for tetracyclines, they are contraindicated in young children and pregnant women. However, the use of fluoroquinolone monotherapy in brucellosis patients has led to frequent relapses and failures [13] [14] [15] , and the combination of a fluoroquinolone with another antibiotic (especially rifampicin) is no more effective than currently available antibiotic regimens [3, 4, 16] . Thus, fluoroquinolones are currently not recommended as a first-line drug to treat brucellosis patients [3] .
Several hypotheses have been raised to explain the discrepancies between the in vitro and in vivo activities of fluoroquinolones. First, fluoroquinolones have no bactericidal activity against Brucella spp. either in vitro [17, 18] or in animal models [19, 20] . Moreover, Brucella sp. multiply in acidic phagosomes both in professional and non-professional phagocytic cells [11, 12] . Although fluoroquinolones are concentrated within eukaryotic cells, their activity is dramatically reduced at acidic pH [17, 18] . Finally, in vivo selection of fluoroquinolone-resistant mutants in Brucella sp. has been evoked [21] . In vitro, only low variations in fluoroquinolone MICs between various Brucella strains has been reported [7] [8] [9] [10] 18] , although there are rare exceptions [22] .
Two major fluoroquinolones resistance mechanisms have been described so far [23, 24] : (i) mutations in type II topoisomerase genes, encoding DNA gyrase and type IV topoisomerase, which are the natural targets of fluoroquinolone action; and (ii) overexpression of efflux pumps reducing drug accumulation in bacteria. Turkmani et al. [25] recently reported selection of gyrA-mediated fluoroquinolone resistance in Brucella abortus. In the present study, we further explored fluoroquinolone resistance mechanisms in Brucella melitensis.
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Material and methods

Bacterial strains
Brucella melitensis 16M (ATCC 23456) was used in all experiments. Brucella melitensis 16M was grown on Columbia agar supplemented with 5% sheep blood (bioMérieux, Lyon, France) at 37 C in a 5% CO 2 -enriched atmosphere in a biosafety level 3 laboratory. Escherichia coli ATCC 25922 and Staphylococcus aureus ATCC 25923 were used as control strains for MIC determination.
Antibiotics
The following antibiotics were tested: moxifloxacin (Bayer Pharma, Puteaux, France), ciprofloxacin (Bayer Pharma), levofloxacin (sanofi-aventis, Paris, France), doxycycline (Arrow, Lyon, France), rifampicin (sanofi-aventis), gentamicin (Dakota Pharma, Paris, France), co-trimoxazole (Roche, Neuilly-sur-Seine, France) and erythromycin (CSP, Cournon, France). Antibiotics were dissolved as recommended by the manufacturers, prepared in aqueous solutions at a concentration of 2 mg/mL and stored at -80 C until use.
Selection of fluoroquinolone-resistant mutants
Brucella melitensis 16M was grown on Columbia agar with 5% sheep blood at 37 C Twelve subcultures were performed for a total period of 68 days, allowing progressive selection of eight moxifloxacin-resistant mutants. These mutants were then passaged eight times on antibiotic-free blood agar plates to test the stability of the resistant phenotypes and individual colonies were selected for further analysis.
During the antibiotic resistance selection process, the intermediate-resistant populations were also harvested and kept frozen at -80 C for further analysis. were determined using the same procedure but the incubation time was 18 h.
Minimum inhibitory concentration determination
DNA gyrase and topoisomerase IV gene sequencing
Bacterial suspensions were prepared by harvesting a single colony from each mutant in 1 mL of sterile distilled water. Bacteria were inactivated by heating at 90C for 2 h.
DNA was extracted using the QIAmp DNA Mini Kit (QIAGEN S.A., Courtaboeuf, France) according to manufacturer's instructions. Primers used for polymerase chain reaction (PCR) amplification and DNA sequencing are described in Table 1 and were purchased from MGW-Biotech (Roissy, France). PCR primers were first designed to amplify the quinolone resistance-determining regions (QRDRs) of gyrA, gyrB, parC and parE using the B. melitensis 16M genome sequence available in GenBank (NC 003317 and NC 003318). For B. melitensis 16M and two fluoroquinolone-resistant mutants, whole DNA sequences of gyrA and parC genes were determined using the primer pairs described in Table 1 . The specificity of the primers was checked using BLAST alignment (BLASTn; National Center for Biotechnology Information, Bethesda, MD). PCR was performed using the Pwo Master Kit (Roche Diagnostics, 
Evaluation of efflux pump overexpression
Moxifloxacin 
NorMI and NorMII gene sequencing
NormI and NormII are currently the only efflux pumps that have been characterised as functionally active in B. melitensis 16M [26] . They belong to the MATE (multidrug and toxic extrusion) efflux pump family and have been shown to be specifically susceptible to PAN [26] . Whole NorMI and NorMII genes plus a 250 bp upstream A c c e p t e d M a n u s c r i p t DNA fragment were amplified and sequenced in B. melitensis 16M and two fluoroquinolone-resistant mutants using the primers indicated in Table 1 to check for the presence of mutations in the genes or in promoters.
Results
Selection of fluoroquinolone resistance in Brucella melitensis 16M
Following a total of 12 passages (i.e. 68 days) of B. melitensis 16M in the presence of moxifloxacin concentrations ranging from 0.25 mg/L to 256 mg/L, eight independent resistant mutants were selected, termed M1 to M8 (Table 2) . First, five passages were performed every 3-5 days with no evident resistance selection. Then, seven additional passages were performed every 7-10 days and resistance selection rapidly occurred. Moxifloxacin resistance was stable in all mutants after eight further subcultures in antibiotic-free medium.
Minimum inhibitory concentration determination
In Table 2 ). The presence of Ala67Val substitution was correlated with a higher level of cross-resistance to levofloxacin and ciprofloxacin.
Evaluation of efflux pump overexpression
None of the tested EPIs displayed a bacteriostatic effect against B. melitensis 16M on its own, except PAN at concentrations >154 M, and CCCP that completely inhibited bacterial growth at concentrations ranging from 25 M to 100 M. CCCP activity could not be evaluated in resistant mutants. As shown in Table 3 , only PAN significantly reduced the moxifloxacin MIC (by a factor of two to eight) in all moxifloxacin-resistant mutants, but not in B. melitensis 16M. Furthermore, a doseeffect relationship was demonstrated (Table 3) . PAN only displayed a weak effect on ciprofloxacin and levofloxacin MICs in moxifloxacin-resistant mutants at a concentration of 154 M (Table 3) .
NorMI and NorMII gene sequencing
No mutations were found in NorMI and NorMII genes or in the 250 bp upstream of the genes for B. melitensis 16M and moxifloxacin-resistant mutants M2 and M6
(moxifloxacin MICs of 32 and 16 mg/L, respectively).
Discussion
The aim of the present study was to evaluate potential resistance mechanisms to fluoroquinolones in Brucella spp. A B. melitensis strain was studied because this Table 2 , a serine is found at GyrA codon position 83 in bacterial species with very low MICs to ciprofloxacin and ofloxacin, e.g. wild-type strains of E. coli [31] and Mycobacterium fortuitum [28] . Ser83Ala substitution has been reported in E. coli strains with a four-fold increase in MICs to these compounds [27] . An alanine residue at codon position 83 is found naturally in Mycobacterium tuberculosis [28] , B. abortus PAN is known to inhibit efflux pumps of the MATE family in different Gram-negative bacterial species [33] . It is a dipeptide amide that acts as an EPI by competing with the fluoroquinolone compounds, thus precluding extrusion of these antibiotics. MATE family efflux pumps have been described in Vibrio parahaemolyticus, Pseudomonas aeruginosa, Campylobacter spp. and Bacteroides thetaiotaomicron [33] . Two putative MATE family efflux pumps have been recently described in B. melitensis, i.e. NorMI and NorMII [26] . Only NorMI has been fully characterised [26] . Thus, we can hypothesise that NorMI and/or NorMII are overexpressed in our B. melitensis M a n u s c r i p t moxifloxacin-resistant mutants. Sequencing NorMI and NorMII genes in two mutants did not reveal any mutation. However, overexpression of efflux pumps is usually related to mutation in local or global regulator genes and less frequently in structural genes [33] . The former genes are currently uncharacterised in B. melitensis.
The moxifloxacin-resistant mutants bearing GyrA A67V substitution displayed only moderate levels of cross-resistance to other fluoroquinolone compounds such as levofloxacin and ciprofloxacin. Cross-resistance can be explained by a strong structural relationship between fluoroquinolone compounds. However, as previously reported [23, 24] , topoisomerase target preference may change according to the 
Conclusion
Our results show that moxifloxacin resistance in B. melitensis 16M first occurred by overexpression of efflux pumps. Higher resistance was then selected by mutation in the gyrA QRDR, leading to Ala67Val substitution in the GyrA QRDR. This substitution was responsible for cross-resistance to other fluoroquinolone compounds. Further work is needed to characterise better the B. melitensis efflux pumps involved in fluoroquinolone resistance, but the MATE family efflux pumps NorMI and NorMII are good candidates.
It should be emphasised that the alanine residue found at position 67 (83 in the E.
coli numbering system) in wild-type B. melitensis GyrA is responsible for low-level resistance to fluoroquinolones, and that bacteria with low-level resistance to fluoroquinolones usually become fully resistant to these compounds through only a one-step mutation [25, 29] . This strengthens current recommendations that fluoroquinolones should not be used as a first-line therapy in brucellosis patients [3] .
A c c e p t e d M a n u s c r i p t M a n u s c r i p t A c c e p t e d M a n u s c r i p t 1 A c c e p t e d M a n u s c r i p t 1 Ver, verapamil; Res, reserpine; SO, sodium orthovanadate; NMP, 1-naphtylmethyl-piperazine; PAN: phenylalanine-arginine--naphthylamide.
